{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-267147","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2022-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.570268+00:00","generated_at":"2026-06-23T01:39:42.976627+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vaxcyte VAX-24 Phase 1/2 meets all endpoints; 2.2mcg dose advances to Phase 3","bullets":["VAX-24 safety profile similar to Prevnar 20 at all doses; no related SAEs or chronic illnesses.","All 24 serotypes met/exceeded regulatory immunogenicity standards at 2.2mcg dose.","Of 20 serotypes common with PCV20, 16 showed higher OPA immune responses; 4 reached statistical significance.","All 4 unique serotypes (2, 9N, 17F, 20B) exceeded standard superiority criteria at all doses.","Milestones: Phase 3 adult data expected 2025; infant Phase 2 initiation in H1 2023; VAX-XP (31-valent) IND in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-267147","json":"https://secwatch.observer/filing/0001193125-22-267147.json","markdown":"https://secwatch.observer/filing/0001193125-22-267147.md","text":"https://secwatch.observer/filing/0001193125-22-267147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000119312522267147/0001193125-22-267147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000119312522267147/d413834d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T01:39:42.976627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}